MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development DOI Open Access

Farah Khaznadar,

Omar Khaznadar,

Ana G. Petrovic

et al.

Published: May 30, 2024

With around one billion of the world's population affected, era Metabolic-associated fatty liver disease (MAFLD) pandemic has entered global stage. MAFLD is a chronic progressive with accompanying metabolic disorders such as type 2 diabetes mellitus and obesity which can progress asymptomatically to cirrhosis subsequently hepatocellular carcinoma (HCC), for which, date there almost no approved pharmacologic options. Because very complex etiology it affects also extrahepatic organs, multidisciplinary approach required when comes finding an effective safe active substance treatment. The optimal drug should diminish steatosis, fibrosis inflammation in liver, winner authorisation seems be that significantly improves histology. Saroglitazar (Lipaglyn®) was Metabolic dysfunction associated steatohepatitis (MASH) India 2020; however, still being investigated other countries. Despite pharmaceutical industry lagging behind develop ap-proved therapy MAFLD, research been recently intensified many molecules are underway final stages clinical trials expected coming few years. Already this year, first (Rezdiffra™) United States via accelerated procedure treatment i.e. MASH adults. This review underscores most recent information related development drugs treatment, focusing on have come furthest towards approval.

Language: Английский

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development DOI Open Access

Farah Khaznadar,

Omar Khaznadar,

Ana G. Petrovic

et al.

Published: May 30, 2024

With around one billion of the world's population affected, era Metabolic-associated fatty liver disease (MAFLD) pandemic has entered global stage. MAFLD is a chronic progressive with accompanying metabolic disorders such as type 2 diabetes mellitus and obesity which can progress asymptomatically to cirrhosis subsequently hepatocellular carcinoma (HCC), for which, date there almost no approved pharmacologic options. Because very complex etiology it affects also extrahepatic organs, multidisciplinary approach required when comes finding an effective safe active substance treatment. The optimal drug should diminish steatosis, fibrosis inflammation in liver, winner authorisation seems be that significantly improves histology. Saroglitazar (Lipaglyn®) was Metabolic dysfunction associated steatohepatitis (MASH) India 2020; however, still being investigated other countries. Despite pharmaceutical industry lagging behind develop ap-proved therapy MAFLD, research been recently intensified many molecules are underway final stages clinical trials expected coming few years. Already this year, first (Rezdiffra™) United States via accelerated procedure treatment i.e. MASH adults. This review underscores most recent information related development drugs treatment, focusing on have come furthest towards approval.

Language: Английский

Citations

1